Skip to main content

videos

Joshua Richter, MD
Conference Coverage
08/20/2025
Joshua Richter, MD
At the 2025 Great Debates in Hematologic Malignancies meeting, Joshua Richter, MD, argues for the benefits of dual maintenance therapy following autologous stem cell transplantation to improve responses among patients with multiple myeloma.
At the 2025 Great Debates in Hematologic Malignancies meeting, Joshua Richter, MD, argues for the benefits of dual maintenance therapy following autologous stem cell transplantation to improve responses among patients with multiple myeloma.
At the 2025 Great Debates in...
08/20/2025
Oncology
Joshua Richter, MD
Conference Coverage
08/20/2025
Joshua Richter, MD
At the 2025 Great Debates in Hematologic Malignancies meeting, Joshua Richter, MD, argues for the benefits of dual maintenance therapy following autologous stem cell transplantation to improve responses among patients with multiple myeloma.
At the 2025 Great Debates in Hematologic Malignancies meeting, Joshua Richter, MD, argues for the benefits of dual maintenance therapy following autologous stem cell transplantation to improve responses among patients with multiple myeloma.
At the 2025 Great Debates in...
08/20/2025
Oncology
Noa Biran, MD
Conference Coverage
08/20/2025
Noa Biran, MD
Noa Biran, MD participated in a debate on the role of dual maintenance therapy following transplant for patients with multiple myeloma at the 2025 Great Debates in Hematologic Malignancies meeting.
Noa Biran, MD participated in a debate on the role of dual maintenance therapy following transplant for patients with multiple myeloma at the 2025 Great Debates in Hematologic Malignancies meeting.
Noa Biran, MD participated in a...
08/20/2025
Oncology
Noa Biran, MD
Conference Coverage
08/20/2025
Noa Biran, MD
Noa Biran, MD participated in a debate on the role of dual maintenance therapy following transplant for patients with multiple myeloma at the 2025 Great Debates in Hematologic Malignancies meeting.
Noa Biran, MD participated in a debate on the role of dual maintenance therapy following transplant for patients with multiple myeloma at the 2025 Great Debates in Hematologic Malignancies meeting.
Noa Biran, MD participated in a...
08/20/2025
Oncology
Faith Davies, MD
Conference Coverage
08/06/2025
Faith E. Davies, MD
At the 2025 Great Debates in Hematologic Malignancies meeting, Faith Davies, MD, participated in a debate on the benefits of treating patients with high-risk smoldering multiple myeloma.
At the 2025 Great Debates in Hematologic Malignancies meeting, Faith Davies, MD, participated in a debate on the benefits of treating patients with high-risk smoldering multiple myeloma.
At the 2025 Great Debates in...
08/06/2025
Oncology
Faith Davies, MD
Conference Coverage
08/06/2025
Faith E. Davies, MD
At the 2025 Great Debates in Hematologic Malignancies meeting, Faith Davies, MD, participated in a debate on the benefits of treating patients with high-risk smoldering multiple myeloma.
At the 2025 Great Debates in Hematologic Malignancies meeting, Faith Davies, MD, participated in a debate on the benefits of treating patients with high-risk smoldering multiple myeloma.
At the 2025 Great Debates in...
08/06/2025
Oncology
Peter Voorhees, MD
Conference Coverage
08/06/2025
Peter Voorhees, MD
At the 2025 Great Debates in Hematologic Malignancies meeting, Peter Voorhees, MD, discusses strategies for treating patients with high-risk smoldering multiple myeloma to prevent or slow disease progression, citing findings from the phase 3...
At the 2025 Great Debates in Hematologic Malignancies meeting, Peter Voorhees, MD, discusses strategies for treating patients with high-risk smoldering multiple myeloma to prevent or slow disease progression, citing findings from the phase 3...
At the 2025 Great Debates in...
08/06/2025
Oncology
Peter Voorhees, MD
Conference Coverage
08/06/2025
Peter Voorhees, MD
At the 2025 Great Debates in Hematologic Malignancies meeting, Peter Voorhees, MD, discusses strategies for treating patients with high-risk smoldering multiple myeloma to prevent or slow disease progression, citing findings from the phase 3...
At the 2025 Great Debates in Hematologic Malignancies meeting, Peter Voorhees, MD, discusses strategies for treating patients with high-risk smoldering multiple myeloma to prevent or slow disease progression, citing findings from the phase 3...
At the 2025 Great Debates in...
08/06/2025
Oncology
Naval Daver, MD
Conference Coverage
08/05/2025
Naval G. Daver
At the 2025 Great Debates in Hematologic Malignancies meeting, Naval Daver, MD, debates against minimal residual disease negativity as the predominate determining factor for transplant eligibility among patients with acute myeloid leukemia.
At the 2025 Great Debates in Hematologic Malignancies meeting, Naval Daver, MD, debates against minimal residual disease negativity as the predominate determining factor for transplant eligibility among patients with acute myeloid leukemia.
At the 2025 Great Debates in...
08/05/2025
Oncology
Naval Daver, MD
Conference Coverage
08/05/2025
Naval G. Daver
At the 2025 Great Debates in Hematologic Malignancies meeting, Naval Daver, MD, debates against minimal residual disease negativity as the predominate determining factor for transplant eligibility among patients with acute myeloid leukemia.
At the 2025 Great Debates in Hematologic Malignancies meeting, Naval Daver, MD, debates against minimal residual disease negativity as the predominate determining factor for transplant eligibility among patients with acute myeloid leukemia.
At the 2025 Great Debates in...
08/05/2025
Oncology